Jiangxi Fushine Pharmaceutical Co., Ltd. (300497.SZ)
CNY 9.12
(-0.44%)
CNY 9.12
(-0.44%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -229.38 Million CNY | -71.24% |
| 2022 | -133.95 Million CNY | -334.99% |
| 2021 | 57 Million CNY | -85.27% |
| 2020 | 386.99 Million CNY | 4.8% |
| 2019 | 369.26 Million CNY | 59.74% |
| 2018 | 231.16 Million CNY | 16.99% |
| 2017 | 197.58 Million CNY | 4.8% |
| 2016 | 188.54 Million CNY | 71.55% |
| 2015 | 109.9 Million CNY | 80.66% |
| 2014 | 60.83 Million CNY | 28.11% |
| 2013 | 47.48 Million CNY | 16.1% |
| 2012 | 40.9 Million CNY | 11.13% |
| 2011 | 36.8 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | -41.46 Million CNY | -62.77% |
| 2024 Q1 | 4.1 Million CNY | 102.86% |
| 2024 Q2 | -25.47 Million CNY | -720.94% |
| 2023 Q3 | -18.17 Million CNY | 46.67% |
| 2023 FY | -229.38 Million CNY | -71.24% |
| 2023 Q1 | -33.8 Million CNY | 81.09% |
| 2023 Q4 | -143.32 Million CNY | -688.4% |
| 2023 Q2 | -34.08 Million CNY | -0.84% |
| 2022 Q2 | 16.39 Million CNY | -42.62% |
| 2022 Q3 | -173.62 Thousand CNY | -101.06% |
| 2022 Q4 | -178.75 Million CNY | -102853.57% |
| 2022 FY | -133.95 Million CNY | -334.99% |
| 2022 Q1 | 28.57 Million CNY | 123.12% |
| 2021 Q1 | 88.79 Million CNY | 265.38% |
| 2021 Q2 | 88.19 Million CNY | -0.68% |
| 2021 Q4 | -123.61 Million CNY | -3510.32% |
| 2021 FY | 57 Million CNY | -85.27% |
| 2021 Q3 | 3.62 Million CNY | -95.89% |
| 2020 Q3 | 90.14 Million CNY | -46.15% |
| 2020 Q1 | 105.13 Million CNY | -7.62% |
| 2020 Q4 | 24.3 Million CNY | -73.04% |
| 2020 FY | 386.99 Million CNY | 4.8% |
| 2020 Q2 | 167.4 Million CNY | 59.22% |
| 2019 Q1 | 53.88 Million CNY | 82.51% |
| 2019 Q4 | 113.8 Million CNY | -8.12% |
| 2019 FY | 369.26 Million CNY | 59.74% |
| 2019 Q3 | 123.86 Million CNY | 59.43% |
| 2019 Q2 | 77.69 Million CNY | 44.18% |
| 2018 Q3 | 48.64 Million CNY | -40.15% |
| 2018 FY | 231.16 Million CNY | 16.99% |
| 2018 Q4 | 29.52 Million CNY | -39.31% |
| 2018 Q2 | 81.28 Million CNY | 13.35% |
| 2018 Q1 | 71.7 Million CNY | 70.84% |
| 2017 Q3 | 43.69 Million CNY | -17.39% |
| 2017 Q2 | 52.88 Million CNY | -10.41% |
| 2017 Q4 | 41.97 Million CNY | -3.93% |
| 2017 FY | 197.58 Million CNY | 4.8% |
| 2017 Q1 | 59.03 Million CNY | 26.07% |
| 2016 FY | 188.54 Million CNY | 71.55% |
| 2016 Q1 | 41.78 Million CNY | 36.6% |
| 2016 Q3 | 49.87 Million CNY | -0.36% |
| 2016 Q4 | 46.82 Million CNY | -6.12% |
| 2016 Q2 | 50.05 Million CNY | 19.79% |
| 2015 Q2 | 26 Million CNY | 17.47% |
| 2015 Q4 | 30.58 Million CNY | -1.88% |
| 2015 Q3 | 31.17 Million CNY | 19.89% |
| 2015 Q1 | 22.13 Million CNY | 81.05% |
| 2015 FY | 109.9 Million CNY | 80.66% |
| 2014 FY | 60.83 Million CNY | 28.11% |
| 2014 Q1 | 13.79 Million CNY | 0.0% |
| 2014 Q4 | 12.22 Million CNY | 0.0% |
| 2013 FY | 47.48 Million CNY | 16.1% |
| 2012 FY | 40.9 Million CNY | 11.13% |
| 2011 FY | 36.8 Million CNY | 0.0% |